Simone A. Huygens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Simone A. Huygens has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Matthijs Versteegh
Department of Research, Development and Medicines, Dutch Health Care Institute, Diemen, The Netherlands
10 shared publications - Balázs Nagy
Center for Health Technology Assessment Semmelweis University Budapest Hungary
8 shared publications - Heleen Vellekoop
Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands
8 shared publications - László Szilberhorn
Syreon Research Institute, Budapest, Hungary
8 shared publications - Maureen P. M. H. Rutten-Van MölKen
Erasmus School of Health Policy & Management, Erasmus Universiteit Rotterdam, Rotterdam, The Netherlands
8 shared publications - Rositsa Koleva-Kolarova
Health Economics Research Centre, University of Oxford, Oxford, UK
8 shared publications
Latest Publications
- Open Access
- 21 March 2026
- Published by Springer Nature in PharmacoEconomics
- Vol. 44 (7) , 865-878
The Cost Utility of Rhythm Control Treatment Sequences in Patients with Atrial Fibrillation: Anti-arrhythmic Drugs Versus Catheter Ablation
Despite evidence on the cost effectiveness of catheter ablation (CA) as a rhythm control strategy in patients with atrial fibrillation, CAs form a substantial share of medical resource consumption, raising questions about optimal timing and maximum CAs per patient. This study addresses these questions using a newly developed open source model integrating observational and clinical trial data. The objective was to estimate the cost effectiveness of rhythm control strategies including anti-arrhythmic drugs (AADs) and/or CA in different sequences from a societal perspective in the Netherlands. Time to atrial fibrillation symptom recurrence after a CA was estimated using parametric survival functions estimated on health insurance data (n = 24,286). Relative efficacy of CAs versus AADs was derived from meta-analyses, accounting for previous treatment exposure. Six treatment lines were modeled, incorporating AADs and CAs as rhythm control strategies. Medical and societal costs were included and the model had a lifetime time horizon. Model results were generated in 2024 Euros using Dutch input data with a cost-per-quality-adjusted life-year threshold of €20,000. For the probabilistic sensitivity analyses, we simultaneously varied all parameters across 1000 model runs with 5000 patients each. Treatment sequences including at least one CA were cost effective compared with only AADs. Catheter ablation costs are counterbalanced by reduced medical resource consumption in the years following CA. 51.6% of patients with first-line CA remain symptom free over a lifetime versus 6.9% with AADs. The most cost-effective strategy starts with CA, manages atrial fibrillation recurrences with AADs, and uses a maximum of three repeat ablations. Our model suggests that rhythm control with at least one CA is cost effective compared with only AADs in patients with atrial fibrillation requiring rhythm control. Within shared decision making, first-line CA, followed by AADs to manage atrial fibrillation recurrences, with a maximum of three repeat ablations, represents the most cost-effective strategy for patients with symptomatic atrial fibrillation requiring rhythm control.
- 21 March 2026
- Published by Springer Nature in PharmacoEconomics
- Vol. 44 (7) , 865-878
Open AccessThe Cost Utility of Rhythm Control Treatment Sequences in Patients with Atrial Fibrillation: Anti-arrhythmic Drugs Versus Catheter Ablation
Despite evidence on the cost effectiveness of catheter ablation (CA) as a rhythm control strategy in patients with atrial fibrillation, CAs form a substantial share of medical resource consumption, raising questions about optimal timing and maximum CAs per patient. This study addresses these questions using a newly developed open source model integrating observational and clinical trial data. The objective was to estimate the cost effectiveness of rhythm control strategies including anti-arrhythmic drugs (AADs) and/or CA in different sequences from a societal perspective in the Netherlands. Time to atrial fibrillation symptom recurrence after a CA was estimated using parametric survival functions estimated on health insurance data (n = 24,286). Relative efficacy of CAs versus AADs was derived from meta-analyses, accounting for previous treatment exposure. Six treatment lines were modeled, incorporating AADs and CAs as rhythm control strategies. Medical and societal costs were included and the model had a lifetime time horizon. Model results were generated in 2024 Euros using Dutch input data with a cost-per-quality-adjusted life-year threshold of €20,000. For the probabilistic sensitivity analyses, we simultaneously varied all parameters across 1000 model runs with 5000 patients each. Treatment sequences including at least one CA were cost effective compared with only AADs. Catheter ablation costs are counterbalanced by reduced medical resource consumption in the years following CA. 51.6% of patients with first-line CA remain symptom free over a lifetime versus 6.9% with AADs. The most cost-effective strategy starts with CA, manages atrial fibrillation recurrences with AADs, and uses a maximum of three repeat ablations. Our model suggests that rhythm control with at least one CA is cost effective compared with only AADs in patients with atrial fibrillation requiring rhythm control. Within shared decision making, first-line CA, followed by AADs to manage atrial fibrillation recurrences, with a maximum of three repeat ablations, represents the most cost-effective strategy for patients with symptomatic atrial fibrillation requiring rhythm control.
- 1 March 2024
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 65 (3)
How microsimulation translates outcome estimates to patient lifetime event occurrence in the setting of heart valve disease
Summary: Treatment decisions in healthcare often carry lifelong consequences that can be challenging to foresee. As such, tools that visualize and estimate outcome after different lifetime treatment strategies are lacking and urgently needed to support clinical decision-making in the setting of rapidly evolving healthcare systems, with increasingly numerous potential treatments. In this regard, microsimulation models may prove to be valuable additions to current risk-prediction models. Notable advantages of microsimulation encompass input from multiple data sources, the ability to move beyond time-to-first-event analysis, accounting for multiple types of events and generating projections of lifelong outcomes. This review aims to clarify the concept of microsimulation, also known as individualized state-transition models, and help clinicians better understand its potential in clinical decision-making. A practical example of a patient with heart valve disease is used to illustrate key components of microsimulation models, such as health states, transition probabilities, input parameters (e.g. evidence-based risks of events) and various aspects of mortality. Finally, this review focuses on future efforts needed in microsimulation to allow for increasing patient-tailoring of the models by extending the general structure with patient-specific prediction models and translating them to meaningful, user-friendly tools that may be used by both clinician and patient to support clinical decision-making.
- 1 March 2024
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 65 (3)
How microsimulation translates outcome estimates to patient lifetime event occurrence in the setting of heart valve disease
Summary: Treatment decisions in healthcare often carry lifelong consequences that can be challenging to foresee. As such, tools that visualize and estimate outcome after different lifetime treatment strategies are lacking and urgently needed to support clinical decision-making in the setting of rapidly evolving healthcare systems, with increasingly numerous potential treatments. In this regard, microsimulation models may prove to be valuable additions to current risk-prediction models. Notable advantages of microsimulation encompass input from multiple data sources, the ability to move beyond time-to-first-event analysis, accounting for multiple types of events and generating projections of lifelong outcomes. This review aims to clarify the concept of microsimulation, also known as individualized state-transition models, and help clinicians better understand its potential in clinical decision-making. A practical example of a patient with heart valve disease is used to illustrate key components of microsimulation models, such as health states, transition probabilities, input parameters (e.g. evidence-based risks of events) and various aspects of mortality. Finally, this review focuses on future efforts needed in microsimulation to allow for increasing patient-tailoring of the models by extending the general structure with patient-specific prediction models and translating them to meaningful, user-friendly tools that may be used by both clinician and patient to support clinical decision-making.
- Open Access
- 1 July 2023
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (4) , 321-338
Cost–effectiveness of Alternative NTRK Testing Strategies in Cancer Patients Followed by Histology-Independent Therapy with Entrectinib: an Analysis of Three European Countries
Aim: To explore variations in the cost–effectiveness of entrectinib across different testing strategies and settings. Methods: Four testing strategies where adult cancer patients received entrectin... Plain language summary Histology-independent pharmaceuticals are a new phenomenon in cancer care. Most chemotherapies are prescribed based on the tumor's (primary) location, while histology-indepen...
- 1 July 2023
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (4) , 321-338
Open AccessCost–effectiveness of Alternative NTRK Testing Strategies in Cancer Patients Followed by Histology-Independent Therapy with Entrectinib: an Analysis of Three European Countries
Aim: To explore variations in the cost–effectiveness of entrectinib across different testing strategies and settings. Methods: Four testing strategies where adult cancer patients received entrectin... Plain language summary Histology-independent pharmaceuticals are a new phenomenon in cancer care. Most chemotherapies are prescribed based on the tumor's (primary) location, while histology-indepen...
- Open Access
- 1 July 2023
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (4) , 401-411
Lessons Learned from the Application of the HEcoPerMed Guidance to Three Modeling Case Studies
Background: The HEcoPerMed consortium developed a methodological guidance for the harmonization and improvement of economic evaluations in personalized medicine. Materials & methods: In three thera...
- 1 July 2023
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (4) , 401-411
Open AccessLessons Learned from the Application of the HEcoPerMed Guidance to Three Modeling Case Studies
Background: The HEcoPerMed consortium developed a methodological guidance for the harmonization and improvement of economic evaluations in personalized medicine. Materials & methods: In three thera...
- Open Access
- 1 July 2023
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (4) , 375-385
Cost–effectiveness of Genetic-Based Screening Strategies for Maturity-Onset Diabetes of the Young
Maturity-onset diabetes of the young (MODY) is often misdiagnosed as Type I or II diabetes. This study was designed to assess the cost–effectiveness of MODY screening strategies in Hungary, which i...
- 1 July 2023
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (4) , 375-385
Open AccessCost–effectiveness of Genetic-Based Screening Strategies for Maturity-Onset Diabetes of the Young
Maturity-onset diabetes of the young (MODY) is often misdiagnosed as Type I or II diabetes. This study was designed to assess the cost–effectiveness of MODY screening strategies in Hungary, which i...
- Open Access
- 1 July 2023
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (4) , 339-355
Cost–effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK
The aim of this study was to evaluate the cost–effectiveness of ToxNav©, a multivariant genetic test, to screen for DPYD followed by personalized chemotherapy dosing for metastatic breast cancer in...
- 1 July 2023
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (4) , 339-355
Open AccessCost–effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK
The aim of this study was to evaluate the cost–effectiveness of ToxNav©, a multivariant genetic test, to screen for DPYD followed by personalized chemotherapy dosing for metastatic breast cancer in...
- Open Access
- 1 July 2023
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (4) , 387-399
Cost–effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries
Background: Correct diagnosis of maturity-onset diabetes of the young (MODY), which is often misdiagnosed as Type 1 or 2 diabetes, is important for providing appropriate treatment. Materials & Meth...
- 1 July 2023
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (4) , 387-399
Open AccessCost–effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries
Background: Correct diagnosis of maturity-onset diabetes of the young (MODY), which is often misdiagnosed as Type 1 or 2 diabetes, is important for providing appropriate treatment. Materials & Meth...
- Open Access
- 1 July 2023
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (4) , 305-319
Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation
The implementation of adequate financing and reimbursement of personalized medicine (PM) in Europe is still turbulent. The views and experience of stakeholders about barriers in financing and reimb...
- 1 July 2023
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (4) , 305-319
Open AccessFinancial incentives to promote personalized medicine in Europe: an overview and guidance for implementation
The implementation of adequate financing and reimbursement of personalized medicine (PM) in Europe is still turbulent. The views and experience of stakeholders about barriers in financing and reimb...
- Open Access
- 1 July 2023
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (4) , 357-374
Budget Impact and Transferability of Cost–effectiveness of DPYD Testing in Metastatic Breast Cancer in Three Health Systems
The cost–effectiveness and budget impact of introducing extended DPYD testing prior to fluoropyrimidine-based chemotherapy in metastatic breast cancer patients in the UK, The Netherlands and Hungar... Tweetable abstract The cost–effectiveness and budget impact of extended DPYD testing with ToxNav prior to capecitabine/5-fluorouracil in metastatic breast cancer in the UK, The Netherlands and Hung...
- 1 July 2023
- Published by Taylor & Francis in Personalized Medicine
- Vol. 20 (4) , 357-374
Open AccessBudget Impact and Transferability of Cost–effectiveness of DPYD Testing in Metastatic Breast Cancer in Three Health Systems
The cost–effectiveness and budget impact of introducing extended DPYD testing prior to fluoropyrimidine-based chemotherapy in metastatic breast cancer patients in the UK, The Netherlands and Hungar... Tweetable abstract The cost–effectiveness and budget impact of extended DPYD testing with ToxNav prior to capecitabine/5-fluorouracil in metastatic breast cancer in the UK, The Netherlands and Hung...
- Open Access
Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model
Background Three sphingosine-1-phosphate receptor (S1PR) modulators are currently available as disease-modifying therapies (DMTs) for relapsing MS in the Netherlands (i.e. fingolimod, ozanimod and ponesimod). We aimed to identify which S1PR modulator yields the highest benefit from a health-economic and societal perspective during a patient’s lifespan. Methods Incorporating Dutch DMT list prices, we used the ErasmusMC/iMTA MS model to compare DMT sequences, including S1PR modulators and eight other DMT classes, for treatment-naive patients with relapsing MS in terms of health outcomes (number of lifetime relapses, time to Expanded Disability Status Scale (EDSS) 6, lifetime quality-adjusted life years (QALYs)) and cost-effectiveness (net health benefit (NHB)). We estimated the influence of list price and EDSS progression on cost-effectiveness outcomes. Results In deterministic and probabilistic analysis, DMT sequences with ponesimod have lower lifetime costs and higher QALYs resulting in a higher average NHB compared to sequences with other S1PR modulators. Ponesimod remains the most cost-effective S1PR modulator when EDSS progression is class-averaged. Given the variable effects on disability progression, list price reductions could make fingolimod but not ozanimod more cost-effective than ponesimod. Conclusion Our model favours ponesimod among the S1PR modulators for the treatment of relapsing MS. This implies that prioritizing ponesimod over other S1PR modulators translates into a more efficacious spending of national healthcare budget without reducing benefit for people with MS. Prioritizing cost-effective choices when counselling patients contributes to affordable and accessible MS care. Highlights Disease-modifying therapies (DMTs) are the largest cost driver in MS Three sphingosine-1-phosphate receptor (S1PR) modulators are used for relapsing MS Our model compares sequences of up to 5 DMTs in terms of health (relapses, progression) and costs Comparing sequences including S1PR modulators, ponesimod is the most cost-effective drug Cost-effectiveness research helps to prioritize when prescribing drugs of a similar class
Open AccessBenefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model
Background Three sphingosine-1-phosphate receptor (S1PR) modulators are currently available as disease-modifying therapies (DMTs) for relapsing MS in the Netherlands (i.e. fingolimod, ozanimod and ponesimod). We aimed to identify which S1PR modulator yields the highest benefit from a health-economic and societal perspective during a patient’s lifespan. Methods Incorporating Dutch DMT list prices, we used the ErasmusMC/iMTA MS model to compare DMT sequences, including S1PR modulators and eight other DMT classes, for treatment-naive patients with relapsing MS in terms of health outcomes (number of lifetime relapses, time to Expanded Disability Status Scale (EDSS) 6, lifetime quality-adjusted life years (QALYs)) and cost-effectiveness (net health benefit (NHB)). We estimated the influence of list price and EDSS progression on cost-effectiveness outcomes. Results In deterministic and probabilistic analysis, DMT sequences with ponesimod have lower lifetime costs and higher QALYs resulting in a higher average NHB compared to sequences with other S1PR modulators. Ponesimod remains the most cost-effective S1PR modulator when EDSS progression is class-averaged. Given the variable effects on disability progression, list price reductions could make fingolimod but not ozanimod more cost-effective than ponesimod. Conclusion Our model favours ponesimod among the S1PR modulators for the treatment of relapsing MS. This implies that prioritizing ponesimod over other S1PR modulators translates into a more efficacious spending of national healthcare budget without reducing benefit for people with MS. Prioritizing cost-effective choices when counselling patients contributes to affordable and accessible MS care. Highlights Disease-modifying therapies (DMTs) are the largest cost driver in MS Three sphingosine-1-phosphate receptor (S1PR) modulators are used for relapsing MS Our model compares sequences of up to 5 DMTs in terms of health (relapses, progression) and costs Comparing sequences including S1PR modulators, ponesimod is the most cost-effective drug Cost-effectiveness research helps to prioritize when prescribing drugs of a similar class